Reasons for ineligibility in phase 1 and 2A HIV vaccine clinical trials at Kenya AIDS vaccine initiative (KAVI), Kenya. - Wikidata - awgldk - TriplyDB

Reasons for ineligibility in phase 1 and 2A HIV vaccine clinical trials at Kenya AIDS vaccine initiative (KAVI), Kenya.

Reasons for ineligibility in phase 1 and 2A HIV vaccine clinical trials at Kenya AIDS vaccine initiative (KAVI), Kenya.

http://www.wikidata.org/entity/Q30399174

about

Evaluation of locally established reference intervals for hematology and biochemistry parameters in Western Kenya Contextualizing willingness to participate: recommendations for engagement, recruitment & enrolment of Kenyan MSM in future HIV prevention trials.Establishment of reference intervals during normal pregnancy through six months postpartum in western Kenya.Reference values for clinical laboratory parameters in young adults in Maputo, Mozambique.Experiences on recruitment and retention of volunteers in the first HIV vaccine trial in Dar es Salam, Tanzania - the phase I/II HIVIS 03 trial Clinical laboratory reference values amongst children aged 4 weeks to 17 months in Kilifi, Kenya: A cross sectional observational study.Diagnostic Accuracy of the HemoCue Hb 301, STAT-Site MHgb and URIT-12 Point-of-Care Hemoglobin Meters in a Central Laboratory and a Community Based Clinic in Durban, South Africa Verification of chemistry reference ranges using a simple method in sub-Saharan Africa.

P2860

Q28546175-C660C739-5EBC-4C20-8A63-819A38B9907A Q30148638-C6AF6FC3-3C93-4F8B-92FA-B4F0BA8508A3 Q33554351-8CB89078-8105-482E-BAD9-F1F0D827E045 Q33610296-C9C57EA9-9E9A-4841-9DDF-99B8DB09AC46 Q33645168-285507C9-866A-45B2-9942-34546114B072 Q33664238-735EABA2-FD93-42FF-A398-9600691657D4 Q35980036-0D18C3DC-3A6E-48ED-898B-3068C03878F2 Q40054523-8834E1EB-D8B3-4ED2-805D-98925D702015

P2860

Reasons for ineligibility in phase 1 and 2A HIV vaccine clinical trials at Kenya AIDS vaccine initiative (KAVI), Kenya.

http://www.wikidata.org/entity/Q30399174

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Reasons for ineligibility in p ...... cine initiative (KAVI), Kenya.

@ast

Reasons for ineligibility in p ...... cine initiative (KAVI), Kenya.

@en

type

label

Reasons for ineligibility in p ...... cine initiative (KAVI), Kenya.

@ast

Reasons for ineligibility in p ...... cine initiative (KAVI), Kenya.

@en

prefLabel

Reasons for ineligibility in p ...... cine initiative (KAVI), Kenya.

@ast

Reasons for ineligibility in p ...... cine initiative (KAVI), Kenya.

@en

P1433

Q30399174-9B0D2AE6-E0A7-4449-BA81-759BE5606824

P1476

Q30399174-3DA6CF42-96F0-4672-B8DE-EE890CCAC59D

P2093

Q30399174-0476F3B4-1230-4B19-8CF8-8CF2B4A3F899

Q30399174-1B0C1C45-17E6-49DA-9DB0-52B0797AB703

Q30399174-1B74A12F-D810-4F02-A220-1D9EC2E5FCCD

Q30399174-4B92C26A-99C3-48D0-8042-EAA8EC7678BF

Q30399174-658640DC-1817-4605-A61E-39A205F6FBE1

Q30399174-69A28644-6850-45CD-A914-C217BA965BCA

Q30399174-8656B599-8300-4643-9FDC-4949683209FE

Q30399174-973551CE-3152-4DE5-B5BC-C8A4E421391F

Q30399174-986A14E4-2DD4-4F6F-B11C-D102AE1EE3D0

Q30399174-A34BE53A-85A0-4CCE-BDD9-E081F34AE710

P2860

Q30399174-0FBD92F7-E098-4C28-8785-24EC1965D068

Q30399174-1CF679AF-8A88-436C-80EF-BA129C02650D

Q30399174-39C5D2D8-FE9E-4D96-AB53-A1A68C94C0B7

Q30399174-3D900452-1ED8-4BE4-A9A8-03237A2205F9

Q30399174-A5346FFA-F2DB-4F00-A24F-29E52FE119E4

Q30399174-AA4A671B-0F4B-4536-B9D3-7F5D8DD95660

Q30399174-B4455F21-6B43-4BCC-9B54-12B6F0795774

Q30399174-C739FA21-4639-4FD2-8D06-714D8ADCBC28

Q30399174-F77734E4-B07D-4B12-8238-8CAD61BDA43D

Q30399174-FD877209-6B0D-4997-A3A9-2CE5AA02059A

P304

Q30399174-CDF48D8C-AB52-4F8F-91D8-DFC2B6A4661D

P31

Q30399174-008B83A6-E702-48E6-AD97-15BCCF25EF7F

P356

Q30399174-3F616DC9-B466-4B7E-90B8-9DEFAE4A782E

P407

Q30399174-7ABE50BC-7FFA-4157-A96A-E88378FFFC83

P433

Q30399174-21B3AC3D-A245-4779-BC79-B32E215AF04E

P478

Q30399174-0B328CDF-FF1A-4C1D-A1C8-341B8074011B

P50

Q30399174-73459DBE-221D-4AA3-815C-F4E9DD61CDCD

Q30399174-CF60EF32-E8B2-4998-A13B-C84597B194D8

P577

Q30399174-38EC0106-68A1-44D4-8168-34932C620FBF

P5875

Q30399174-276B4EC2-AEEC-413C-9B29-D72FB429D877

P698

Q30399174-51DE754D-98A2-4D09-8040-F4D42012AA64

P921

Q30399174-8E06E4DB-40E5-40CD-9A23-6A253CF8812E

Q30399174-BD5F2CC1-FC06-47FD-B49C-B8DDC6CDA811

P932

Q30399174-C6D6A74A-4D1D-4E17-8D15-9BC006DBD27E

P356

JOURNAL.PONE.0014580

P1433

P1476

Reasons for ineligibility in p ...... cine initiative (KAVI), Kenya.

@en

P2093

Bashir Farah

http://www.w3.org/2001/XMLSchema#string

Claudia Schmidt

http://www.w3.org/2001/XMLSchema#string

Frances Priddy

http://www.w3.org/2001/XMLSchema#string

Gloria S Omosa-Manyonyi

http://www.w3.org/2001/XMLSchema#string

Hilda Ogutu

http://www.w3.org/2001/XMLSchema#string

Jacqueline Nyange

http://www.w3.org/2001/XMLSchema#string

Jeckoniah Ndinya-Achola

http://www.w3.org/2001/XMLSchema#string

Kirana Bhatt

http://www.w3.org/2001/XMLSchema#string

Micah Oyaro

http://www.w3.org/2001/XMLSchema#string

Pamela Njuguna

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa

CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa.

Immunohematological reference ranges for adult Ethiopians.

Immunohematological reference ranges for adults from the Central African Republic

Population-based hematologic and immunologic reference values for a healthy Ugandan population.

Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials.

Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.

Non-genetic neutropenia in Africans.

Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.

Genetic neutropenia in people of African origin.

P304

e14580

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0014580

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-01-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49800738

http://www.w3.org/2001/XMLSchema#string

P698

21283743

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

3024980

http://www.w3.org/2001/XMLSchema#string